The report forecasts GSK Pharma sales growth of 15.1% YoY and PAT growth of 22.2% YoY in 2QFY27.
Read this note →GlaxoSmithKline Pharmaceuticals Limited
NSE GLAXO BSE 500660 INE159A01016
0 filings · 0 analysed
2,710.00
+6.68%
over 1 month
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
What the desks said
The factsheet discloses GlaxoSmithKline Pharmaceuticals as an unhedged holding at 3.94% of NAV.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief